Oxford Immunotec Global PLC (OXFD) to Release Quarterly Earnings on Tuesday

Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce its earnings results before the market opens on Tuesday, August 1st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. The firm had revenue of $21.51 million for the quarter, compared to analysts’ expectations of $21.17 million. Oxford Immunotec Global PLC had a negative return on equity of 31.48% and a negative net margin of 25.83%. On average, analysts expect Oxford Immunotec Global PLC to post $-1.06 EPS for the current fiscal year and $-0.78 EPS for the next fiscal year.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 16.26 on Friday. The firm’s market cap is $372.78 million. Oxford Immunotec Global PLC has a one year low of $8.04 and a one year high of $17.38. The stock’s 50 day moving average price is $15.98 and its 200-day moving average price is $14.87.

WARNING: “Oxford Immunotec Global PLC (OXFD) to Release Quarterly Earnings on Tuesday” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/07/30/oxford-immunotec-global-plc-oxfd-to-release-quarterly-earnings-on-tuesday.html.

Several research firms have issued reports on OXFD. BTIG Research restated a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Thursday, May 4th. ValuEngine raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd.

In other Oxford Immunotec Global PLC news, VP Elizabeth M. Keiley sold 4,085 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $15.01, for a total value of $61,315.85. Following the sale, the vice president now owns 25,393 shares of the company’s stock, valued at approximately $381,148.93. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Wrighton-Smith sold 27,168 shares of the firm’s stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $15.94, for a total value of $433,057.92. Following the completion of the sale, the chief executive officer now directly owns 488,836 shares in the company, valued at approximately $7,792,045.84. The disclosure for this sale can be found here. Insiders have sold 147,085 shares of company stock worth $2,275,928 in the last three months. 7.58% of the stock is currently owned by company insiders.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Earnings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply